Levobetaksolol

Levobetaksolol
(IUPAC) ime
	(S)-1-[p-[2-(ciklopropilmetoksi)etil]fenoksi]-3-(izopropilamino)-2-propanol hidrohlorid
Klinički podaci
AHFS/Drugs.com	Mikromedeks, detaljne potrošačke informacije
Identifikatori
CAS broj	93221-48-8
ATC kod	nije dodeljen
PubChem	60657
ChemSpider	54669
UNII	75O9XHA4TU
ChEBI	CHEBI:59254
ChEMBL	CHEMBL1201274
Hemijski podaci
Formula	C18H29NO3
Mol. masa	307,427 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1 ; Key: NWIUTZDMDHAVTP-KRWDZBQOSA-N
Farmakokinetički podaci
Poluvreme eliminacije	20 sata
Farmakoinformacioni podaci
Trudnoća	C(US)
Pravni status
Način primene	topikalno (oftalmički)

Levobetaksolol je lek koji snižava pritisak u oku pri lečenju oboljenja poput glaukoma. On je tipično koristi kao 0.5% oftalmički rastvor levobetaksolol hidrohlorida pod imenom Betakson. Levobetaksolol je antagonist beta adrenergičkog receptora (beta blokator).^[5]

Dejstvo

Levobetaksolol inhibira beta-1 adrenergički receptor. Kad se primenjuje topikalno, on redukuje intraokularni pritisak za 16-23% u zavisnosti od doba dana i osobe. Levobetaksolol ima manje zastupljene kardiovaskularne nuspojave od drugih beta blokatora.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ N.N. Osborne, J.P.M. Wood, G. Chidlow, R. Casson, L. DeSantis, K.-G. Schmidta (2004-02-15). „Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma”. Brain Research Bulletin 62 (6): 525–528. DOI:10.1016/S0361-9230(03)00070-4.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[5] N.N. Osborne, J.P.M. Wood, G. Chidlow, R. Casson, L. DeSantis, K.-G. Schmidta (2004-02-15). „Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma”. Brain Research Bulletin 62 (6): 525–528. DOI:10.1016/S0361-9230(03)00070-4.

[1]

[2]

[3]

[4]

[5]